Business Context and Reporting Period
Company: GSK Plc
Filing Type: Form 6-K (Report of Foreign Issuer)
Reporting Period: Second Quarter (Q2) and First Half (H1) ended 30 June 2018
Issued Date: 25 July 2018
GSK reported Q2 2018 results characterized by sales growth at constant exchange rates (CER) across all three global businesses (Pharmaceuticals, Vaccines, and Consumer Healthcare). The period included the completion of the buyout of Novartis's stake in the Consumer Healthcare Joint Venture on 1 June 2018. Management announced a new major restructuring program and a revised approach to Research and Development (R&D) focusing on the immune system and genetics.
Key Financial Metrics
| Metric | Q2 2018 | Q2 2017 | H1 2018 | H1 2017 |
|---|---|---|---|---|
| Group Sales (Turnover) | £7.3 billion | £7.3 billion | £14.5 billion | £14.7 billion |
| Sales Growth (CER) | +4% | - | +4% | - |
| Total Operating Profit | £779 million | (£20 million) | £2,019 million | £1,698 million |
| Adjusted Operating Profit | £2,102 million | £2,083 million | £4,025 million | £4,062 million |
| Adjusted Operating Margin | 28.8% | 28.5% | 27.7% | 27.6% |
| Total EPS | 9.0p | (3.7p) | 20.2p | 17.7p |
| Adjusted EPS | 28.1p | 27.2p | 52.7p | 52.1p |
| Free Cash Flow (H1) | - | - | £0.8 billion | £0.4 billion |
| Net Debt (30 June 2018) | £23.9 billion | £14.8 billion | - | - |
Segment Performance (Q2 2018)
- Pharmaceuticals: Sales £4.2 billion (-3% AER, +1% CER). Operating margin 35.3%.
- Vaccines: Sales £1.3 billion (+13% AER, +16% CER). Operating margin 28.5%.
- Consumer Healthcare: Sales £1.8 billion (-1% AER, +3% CER). Operating margin 19.3%.
Material Changes vs. Prior Period
- Profitability: Total EPS improved from a loss of 3.7p in Q2 2017 to 9.0p in Q2 2018. This turnaround was driven by reduced impairments, lower restructuring charges, and favorable comparisons to the Priority Review Voucher utilization in Q2 2017.
- Adjusted EPS: Grew 3% at actual exchange rates (AER) and 10% at CER, driven by operating leverage and the reduction of minority interests following the Consumer Healthcare buyout.
- Net Debt: Increased significantly to £23.9 billion from £13.2 billion at year-end 2017. This was primarily due to the £9.3 billion acquisition of Novartis's stake in Consumer Healthcare, dividends paid, and exchange impacts.
- R&D Expenditure: Adjusted R&D decreased 18% AER and 15% CER to £868 million, reflecting prioritization benefits and a favorable comparison to the Priority Review Voucher in the prior year.
Guidance, Outlook, and Management Commentary
2018 Guidance Update
GSK upgraded its full-year 2018 Adjusted EPS growth guidance based on two scenarios regarding the US launch of a generic competitor to Advair:
- Scenario A (No generic launch in 2018): Adjusted EPS growth of 7% to 10% at CER.
- Scenario B (Generic launch from 1 October 2018): Adjusted EPS growth of 4% to 7% at CER.
Guidance reflects increased sales expectations for Shingrix (£600-650 million for 2018) and the earnings contribution from the Consumer Healthcare buyout, offset by pricing pressures in Respiratory.
Restructuring Program
A new major restructuring program was announced, expected to cost £1.7 billion (£0.8 billion cash, £0.9 billion non-cash) over the next three years. It aims to deliver annual cost savings of £400 million by 2021 through supply chain optimization and administrative cost reductions.
R&D Strategy
GSK announced a new R&D approach focusing on the immune system, genetics, and advanced technologies. A strategic collaboration with 23andMe was announced to leverage genetic data for drug target selection. The pipeline includes over 40 new molecular entities (NMEs) with significant data readouts expected between 2018 and 2020.
Risks and Contingencies
- Advair Generic Competition: The timing of a substitutable generic competitor in the US remains a key variable for 2018 earnings.
- Contingent Consideration: Significant liabilities exist related to the ViiV Healthcare acquisition (Shionogi) and Novartis Vaccines acquisition. Re-measurements of these liabilities impacted results significantly in the prior year and continue to be monitored.
- Legal Matters: The Group is involved in significant legal proceedings (product liability, IP, tax, anti-trust). Provisions are made where probable and estimable, but ultimate liability may vary.
Investor Verification Checklist
- Advair Generic Timeline: Verify the status of US generic competition for Advair to determine which 2018 EPS guidance scenario is most likely.
- Shingrix Sales Trajectory: Monitor quarterly sales of Shingrix to ensure they meet the revised £600-650 million full-year expectation.
- Restructuring Execution: Track the progress of the new £1.7 billion restructuring program and the realization of the targeted £400 million annual savings by 2021.
- Net Debt Management: Assess the impact of the increased net debt (£23.9 billion) on interest expenses and liquidity, particularly given the £9.3 billion Consumer Healthcare acquisition.
- Contingent Consideration Volatility: Review future re-measurement charges related to ViiV Healthcare and Novartis Vaccines liabilities, which are sensitive to exchange rates and sales forecasts.
- R&D Pipeline Milestones: Monitor upcoming data readouts for key assets, including the dolutegravir+lamivudine regimen and the BCMA antibody-drug conjugate (2857916).